Combinations of quality and frequency of immunization activities to stop and prevent poliovirus transmission in the high-risk area of northwest Nigeria

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Duintjer Tebbens, Radboud J ^a   Pallansch, Mark A ^b   Wassilak, Steven G F ^c   Cochi, Stephen L ^c   Thompson, Kimberly M ^a  

^a Kid Risk Inc   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

ARTICLE; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; MATHEMATICAL MODEL; NIGERIA; POLIOMYELITIS; SENSITIVITY ANALYSIS; SUPPLEMENTAL IMMUNIZATION ACTIVITIES; VIRUS TRANSMISSION; DISEASE ERADICATION; IMMUNOLOGY; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL; TRANSMISSION; UTILIZATION; VACCINATION;

POLIOVIRUS;

CHILD, PRESCHOOL; DISEASE ERADICATION; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; MODELS, THEORETICAL; NIGERIA; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; VACCINATION;

EID: 84936124797     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130123     Document Type: Article

References (45)

1. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim J-H, Cochi SL. Pre-eradication vaccine policy options for poliovirus infection and disease control. Risk Anal. 2013; 33(4):516-43. doi: 10.1111/risa.12019 PMID: 23461599
2. Hull HF, Ward NA, Hull BP, Milstien J, de Quadros CA. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet. 1994; 343:1331-7. PMID: 7910329
3. Sabin AB. Strategy for rapid elimination and continuing control of poliomyelitis and other vaccine preventable diseases of children in developing countries. Br Med J (Clin Res Ed). 1986; 292(6519):513-33.
4. World Health Organization. Global Polio Eradication Initiative: Polio Eradication and Endgame Strategic Plan (2013-2018). Geneva: 2013 WHO/POLIO/13.02.
5. World Health Organization. Transmission of wild poliovirus type 2 - Apparent global interruption. Wkly Epidemiol Rec. 2001; 76:95-7. PMID: 11315462
6. Kew OM, Cochi SL, Jafari HS, Wassilak SG, Mast EE, Diop OM, et al. Possible eradication of wild poliovirus type 3 - worldwide, 2012. MMWR Morb Mortal Wkly Rep. 2014; 63(45):1031-3. PMID: 25393222
7. World Health Organization. Global Polio Eradication Initiative - List of wild poliovirus by country 2015. Updated 2015 Jan 6. Available: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Wildpolioviruslist.aspx. Accessed: 2015 Jan 18.
8. Thompson KM, Kalkowska DA, Duintjer Tebbens RJ. Managing population immunity to reduce or eliminate the risks of circulation following the importation of live polioviruses Vaccine. 2015; 33(3):1568-77. doi: 10.1016/j.vaccine.2015.02.013 PMID: 25701673
9. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991; 13:926-39. PMID: 1660184
10. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis. 2014; 210(Suppl 1):S412-S23. doi: 10.1093/infdis/jit834 PMID: 25316863
11. Diekmann O, Heesterbeek JA, Metz JA. On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations. Journal of Mathematical Biology. 1990; 28(4):365-82. Epub 1990/01/01. PMID: 2117040
12. Mach O, Tangermann RH, Wassilak SG, Singh S, Sutter RW. Outbreaks of paralytic poliomyelitis during 1996-2012: the changing epidemiology of a disease in the final stages of eradication. J Infect Dis. 2014; 210(Suppl 1):S275-S82. doi: 10.1093/infdis/jit454 PMID: 25316846
13. Burns C, Diop O, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis. 2014; 210(Suppl 1): S283-S93. doi: 10.1093/infdis/jiu295 PMID: 25316847
14. Kew O, Morris-Glasgow V, Landaverde M, Burns C, Shaw J, Garib Z, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002; 296(5566):356-9. PMID: 11896235
15. Duintjer Tebbens RJ, Pallansch MA, Kim J-H, Burns CC, Kew OM, Oberste MS, et al. Review: Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine-Derived Polioviruses (cVDPVs). Risk Anal. 2013; 23(4):680-702.
16. World Health Organization. Polio Eradication Initiative. Cessation of Routine Oral Polio Vaccine (OPV) use after Global Polio Eradication. Framework for National Policy Makers in OPV-using Countries. Geneva, Switzerland: 2005 WHO/POL/05.02.
17. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health. 2008; 98(7):1322-30. doi: 10.2105/AJPH.2007.122192 PMID: 18511720
18. Centers for Disease Control and Prevention. Resurgence of wild poliovirus type 1 transmission and consequences of importation - 21 previously polio-free countries, 2002-2005. MMWR Morb Mortal Wkly Rep. 2006; 55(6):145-50. PMID: 16484977
19. Centers for Disease Control and Prevention. Outbreaks following wild poliovirus importations - Europe, Africa, and Asia, January 2009-September 2010. MMWR Morb Mortal Wkly Rep. 2010; 59(43):1393-9. Epub 2010/11/05. mm5943a1 [pii]. PMID: 21048560
20. National Population Commission Nigeria and ICF International. Nigeria Demographic and Health Survey 2013. Abuja, Nigeria, and Rockville, Maryland, USA NPC and ICF International; 2014. Available from: https://dhsprogram.com/pubs/pdf/FR293/FR293.pdf.
21. Wassilak SGF, Pate MA, Wannemuehler K, Jenks J, Burns C, Chenoweth P, et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis. 2011; 203(7):898-909. Epub 2011/03/16. doi: 10.1093/infdis/jiq140 PMID: 21402542
22. Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Mwanza M, Corander J, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med. 2010; 326(25):2360-9.
23. Duintjer Tebbens RJ, Kalkowska DA, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis. 2014; 14(45). doi: 10.1186/1471-2334-14-45 PMID: 24472313
24. Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. 2014; 210(Suppl 1):S475-S84. doi: 10.1093/infdis/jit845 PMID: 25316870
25. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013; 23(4):703-49.
26. Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Thompson KM. Modeling undetected live poliovirus circulation after apparent interruption of transmission: Implications for surveillance and vaccination. BMC Infect Dis. 2015; 15(66):1. doi: 10.1186/s12879-015-0791-5 PMID: 25886823
27. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, et al. Expert review on poliovirus immunity and transmission. Risk Anal. 2013; 33(4):544-605. doi: 10.1111/j.1539-6924.2012.01864.x PMID: 22804479
28. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, et al. Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs. Risk Anal. 2013; 33(4):606-46. doi: 10.1111/risa.12031 PMID: 23550968
29. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. World Population Prospects: The 2012 Revision 2013. Available: http://esa.un.org/unpd/wpp/index.htm. Accessed 2013 Sep 11.
30. Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010; 172(11):1213-29. Epub 2010/10/28. doi: 10.1093/aje/kwq320 PMID: 20978089
31. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. J Infect Dis. 2014; 210(Suppl 1):S398-S411. doi: 10.1093/infdis/jit844 PMID: 25316861
32. World Health Organization. Global Polio Eradication Initiative - circulating vaccine-derived poliovirus cases 2000-2015 2015. Updated 2015 Jan 6. Available: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccinederivedpoliovirus.aspx. Accessed 2015 Jan 6.
33. Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis. 2014; 210(Suppl 1):S485-S97. doi: 10.1093/infdis/jit838 PMID: 25316871
34. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal. 2013; 33(4):647-63. doi: 10.1111/j.1539-6924.2012.01891.x PMID: 22985171
35. Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: An economic analysis. Lancet. 2007; 369(9570):1363-71. PMID: 17448822
36. Barau I, Zubairu M, Mwanza MN, Seaman VY. Improving polio vaccination coverage in Nigeria through the use of geographic information system technology. J Infect Dis. 2014; 210 Suppl 1:S102-S10. doi: 10.1093/infdis/jiu010 PMID: 25316823
37. Thompson KM. Polio endgame management: Focusing on performance with or without inactivated poliovirus vaccine. Lancet. 2014; 384(9953):1480-2. doi: 10.1016/S0140-6736(14)60983-1 PMID: 25018123
38. Jafari H, Deshpande JM, Sutter RW, Bahl S, Verma H, Ahmad M, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science. 2014; 345(6199):922-5. doi: 10.1126/science.1255006 PMID: 25146288
39. Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012; 8(4):e1002599. doi: 10.1371/journal.ppat.1002599 PMID: 22532797
40. The Cuba IPV Study Collaborative Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med. 2007; 356(15):1536-44. PMID: 17429085
41. Anis E, Kopel E, Singer S, Kaliner E, Moerman L, Moran-Gilad J, et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill. 2013; 18(38):pii = 20586.
42. Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SGF, et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis. 2015; 211(11):1800-12. doi: 10.1093/infdis/jiu674 PMID: 25505296
43. Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication. Exp Rev Vaccines. 2014; 13(2):221-34. doi: 10.1586/14760584.2014.864563 PMID: 24308581
44. Bahl S, Kumar R, Menabde N, Thapa A, McFarland J, Swezy V, et al. Polio-free certification and lessons learned - South-East Asia region, march 2014. MMWR Morb Mortal Wkly Rep. 2014; 63(42):941-6. PMID: 25340910
45. Thompson KM, Duintjer Tebbens RJ. The differential impact of oral poliovirus vaccine formulation choices on type-specific population immunity to poliovirus transmission (in preparation).